Abstract: The present invention relates to glutamate decarboxylase (GAD) gene sequence isolated from Oryza sativa (cv Rasi) and their corresponding encoded polypeptides that confer the traits of improved nitrogen use efficiency in plants. The present invention further relates to the use of these nucleic acid molecules and polypeptides in making transgenic plants, plant cells, plant materials or seeds of a plant having improved nitrogen use efficiency.

Abstract: The present invention describes a palatable and orally administrable form of composition comprising proteins, galactomannans and base matrix optionally along with acceptable additives.

Abstract: The present invention relates to glutamate decarboxylase (GAD) gene sequence isolated from Oryza sativa (cv Rasi) and their corresponding encoded polypeptides that confer the traits of improved nitrogen use efficiency in plants. The present invention further relates to the use of these nucleic acid molecules and polypeptides in making transgenic plants, plant cells, plant materials or seeds of a plant having improved nitrogen use efficiency.

Abstract: The present invention relates to method for generating plants having altered architecture by introducing into plants, isolated nucleic acid molecules that can be used to produce transgenic plants characterized by altered plant architecture, carbon and nitrogen partitioning, enhanced biomass and or improved harvestable yield and to plants so generated and parts of these plants. More particularly, the present invention relates to a method for modifying a plant so as to produce a plant exhibiting an altered phenotype. Also provided are isolated nucleic sequence that encodes GAD polypeptide, vectors capable of expressing such nucleic acid molecules, host cells containing such vectors, and polypeptide encoded by such nucleic acids.

Abstract: The invention describes a highly improved, reproducible and a consistent method of transformation and regeneration that results in obtaining 12-15% transgenic plants. The present invention relates to a method of selecting genetically transformed Sunflower explants based on their ability to utilize Xylose as a sole carbohydrate source. Further disclosed is the nucleic acid sequence of the Xylose Isomerase gene, vector construction for incorporation of the selection marker gene and the process of Agrobacterium Mediated Transformation of target host plant with the vector comprising the gene encoding the enzyme Xylose isomerase under the functional combination of the heterologous regulatory sequences. Also disclosed is the method of selecting the putative transformants post transformation with the said vector that possess a metabolic advantage of utilizing Xylose as a sole carbon source.

Abstract: The present invention relates to a novel transgenic plant having tolerance to salt stress. The plant is transformed with a recombinant nucleic acid encoding glutamic acid decarboxylase isolated from Oryza sativa. Still further it also relates to a method of producing the transgenic plants that are salt tolerant.

Abstract: The present invention relates to identification and characterization of Phytochemicals and metabolites from Trigonella foenum-graceum extract by Liquid chromatography and Mass spectrometry LC-MS/MS.

Abstract: The present invention relates to the induction of the endogenous MnSOD expression in the chloroplast which scavenges reactive oxygen species in the plant cells and provides the means of cultivating crops in areas where it would not otherwise grow normally on account of environmental stress conditions inclusive of high and low temperatures, drought and ultra violet light, and resistance to herbicides so as to increase yield and improve crop quality.

Abstract: The present invention relates to use of novel bioinformatics approach for predicting and identifying Scaffold/Matrix attachment regions (S/MARs) from different genomic database.

Abstract: The present invention provides therapeutic compositions derived from plants useful for treating diabetes. The present invention also provides methods for screening plant metabolites and constituents to identify therapeutic agents and/or dietary supplements for treating diabetes. The therapeutic compositions can be derived from plants such as Phyllanthus emblica, Azadiractha indica, Terminalia chebula, Mucunapuriens, Curcuma longa, Ficus glomerata, Phyllanthus niruri, Momordica charantia, Euphorbia royleana, Catharanthus roseus, Eugenia jambolana, Emblica officinalis, Gymnema sylvestre, Melia azadirechta, Morinda citrifolia, Pterocarpus marsupium, Tinospora cardifolia, Tribulus teristris, Trigonella foenum graecum, and Withania somnifera.

Abstract: The present invention relates to a synergistic herbal composition for diabetes and related disorders comprising extracts of plant Eugenia of concentration ranging between 10-80% and plant Cinnamomum of concentration ranging between 10-80% optionally along with pharmaceutically acceptable excipients; a method of treating diabetes and related disorders in a subject in need thereof by administering the composition comprising extracts of plant Eugenia of concentration ranging between 10-80% and plant Cinnamomum of concentration ranging between 10-80% optionally along with pharmaceutically acceptable excipients; and a process for preparation of a synergistic herbal composition for diabetes and related disorders, wherein the process comprising steps of: (a) obtaining extracts of Eugenia and Cinnamomum separately using aqueous or organic solvents; and (b) formulating the extracts to arrive at the synergistic composition.

Abstract: The present invention is in relation to an organoleptically improved dietary fiber composition from Trigonella foenum-graecum. In addition, the present invention provides a process to obtain an organoleptically improved dietary fiber composition comprising protein and galactomannans for treatment of diabetes.

Abstract: The invention relates to compositions such as pharmaceutical compositions and comestibles comprising extracts of Terminalia arjuna and methods for preventing or treating diabetes, obesity, cardiovascular disease, cancer and related disease conditions in mammals, such as humans, and uses therefore.

Abstract: The present invention relates to a specifically novel recombinant method of production of the omega-3 fatty acid, Docosahexaenoic acid by a potentially safe recombinant organism Saccharomyces cerevisiae. The invention describes the process of bioconversion of oleic acid to docosahexaenoic acid through a series of enzymatic conversions facilitated through the cloning of the respective genes into appropriate vectors and the final expression of the DHA in the host cell, Yeast.

Abstract: The present invention is concerned with nutritional or pharmaceutical compositions comprising extracts or concentrates of plants and the mixtures thereof belonging to Pinus. sp with specific reference to Pinus pinea. The extracts have been screened and characterized for their activity in the treatment of increased bone resorption and bone formation, osteoporosis in particular. The invention further relates to the use of the extracts as a supplement or a medicament useful in the treatment/alleviation or prevention of diseases or conditions characterized by increased bone resorption and a method of promoting bone growth, maintenance of bone health, comprising the administration of an therapeutically effective amount of the composition containing the extract.

Abstract: The invention describes a highly improved, reproducible and a consistent method of transformation and regeneration that results in obtaining 12-15% transgenic plants. The present invention relates to a method of selecting genetically transformed Sunflower explants based on their ability to utilize Xylose as a sole carbohydrate source. Further disclosed is the nucleic acid sequence of the Xylose Isomerase gene, vector construction for incorporation of the selection marker gene and the process of Agrobacterium Mediated Transformation of target host plant with the vector comprising the gene encoding the enzyme Xylose isomerase under the functional combination of the heterologous regulatory sequences. Also disclosed is the method of selecting the putative transformants post transformation with the said vector that possess a metabolic advantage of utilizing Xylose as a sole carbon source.

Abstract: The present invention relates to the recombinant method used for the production of soluble form of an antibody that binds to CD20 for treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL). The treatment will comprise the use of immunologically active anti-CD20 antibodies; or radiolabeled anti-CD20 antibodies and or cooperative strategies where both labeled and non-labeled antibodies will be used for treatment of NHL. The procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD20, transformation of the constructed nucleic acid sequences into competent bacteria and the sub-cloning of the same into mammalian expression vectors for expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells.

Abstract: The invention relates to compositions and methods for preventing, treating, or managing osteoporosis or conditions which are characterized by increased bone resorption, comprising administration of a prophylactically and therapeutically effective amount of Cissus quadrangularis plant or extracts thereof to a mammal in need of such therapy. Preferably the mammal is human and the compositions comprise of single extract or a combination of extracts thereof. The present invention further relates to extracts which are isolated from different parts of Cissus quadrangularis plant, the preparation of such extracts, the medicaments containing said extracts, and the use of these extracts and constituents for the preparation of a medicament. The present invention also relates to the process for preparing the extracts from various parts of Cissus quadrangularis plant.

Abstract: The present invention relates to the recombinant method used for the production of soluble form of human tissue plasminogen activator variant. In this variant the threonine at position 103 of the endogenous tissue plasminogen activator is replaced by an asparagine leading to a new glycosylation site. At position 117 of the endogenous tissue plasminogen activator asparagine has been replaced by glutamine, leading to the removal of an N linked glycosylation site. At position 296-299 the amino acids lysine, histidine, arginine, and arginine have been replaced by four alanine amino acids. The invention further relates to the de novo synthesis of the nucleic acid sequence encoding tissue plasminogen activator, transformation of the constructed nucleic acid sequences into competent bacteria and sub-cloning of the same into mammalian expression vectors for the expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest have been disclosed.

Abstract: The present invention relates to the recombinant method used for the production of soluble form monoclonal antibody that binds to CD52. The procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD 52, transformation of the constructed nucleic acid sequences into competent bacteria and the sub-cloning of the same into mammalian expression vectors for expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells.